Press Releases Year All News | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | Sep 17, 2021 TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors Sep 13, 2021 TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors Sep 07, 2021 TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference Sep 02, 2021 TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma Aug 26, 2021 TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors Aug 17, 2021 TCR² Therapeutics Announces Upcoming Medical Meetings Update Aug 05, 2021 TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Jul 20, 2021 TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical Officer May 26, 2021 TCR² Therapeutics to Participate in Two Upcoming Conferences in June May 13, 2021 TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
